Impact of the COVID-19 Pandemic on Kidney Diseases Requiring Renal Biopsy: A Single Center Observational Study.
COVID-19 lockdown
COVID-19 pandemic
hemoglobinuria
hypertensive nephropathy
kidney disease
proteinuria
renal biopsy
Journal
Frontiers in physiology
ISSN: 1664-042X
Titre abrégé: Front Physiol
Pays: Switzerland
ID NLM: 101549006
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
03
2021
accepted:
18
06
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
27
7
2021
Statut:
epublish
Résumé
The coronavirus disease-2019 (COVID-19) pandemic impacted healthcare services for kidney disease patients. Lockdown and social distancing were mandated worldwide, resulting in closure of medical services. The diagnosis of various kidney diseases may have been delayed during the COVID-19 pandemic because non-urgent tests and visits were postponed due to closure of medical services during the lockdown. We here report the impact of the COVID-19 pandemic on a total number of 209 native kidney diseases requiring renal biopsy for diagnosis in a retrospective observational study from a tertiary hospital in Germany. The lockdown period in March and April 2020 primarily affected patients admitted to the normal medical ward with a compensatory increased rate of renal biopsies in the postlockdown phase. In addition, there was a shift toward more patients admitted with hemoglobinuria during the COVID-19 pandemic. This phenomenon of an increased number of patients with hemoglobinuria during the COVID-19 pandemic was specifically observed in a subgroup with hypertensive nephropathy requiring renal biopsy and associated with increased proteinuria, not attributed to the COVID-19 lockdown period itself. To our knowledge, this is the first report of identifying a subpopulation susceptible to closure of medical services during the COVID-19 pandemic and diagnostic delay of specific kidney diseases. Therefore, the COVID-19 pandemic should be regarded as a risk factor especially in patients with diseases other than COVID-19 primarily admitted to the normal medical ward.
Sections du résumé
BACKGROUND
BACKGROUND
The coronavirus disease-2019 (COVID-19) pandemic impacted healthcare services for kidney disease patients. Lockdown and social distancing were mandated worldwide, resulting in closure of medical services. The diagnosis of various kidney diseases may have been delayed during the COVID-19 pandemic because non-urgent tests and visits were postponed due to closure of medical services during the lockdown.
METHODS
METHODS
We here report the impact of the COVID-19 pandemic on a total number of 209 native kidney diseases requiring renal biopsy for diagnosis in a retrospective observational study from a tertiary hospital in Germany.
RESULTS
RESULTS
The lockdown period in March and April 2020 primarily affected patients admitted to the normal medical ward with a compensatory increased rate of renal biopsies in the postlockdown phase. In addition, there was a shift toward more patients admitted with hemoglobinuria during the COVID-19 pandemic. This phenomenon of an increased number of patients with hemoglobinuria during the COVID-19 pandemic was specifically observed in a subgroup with hypertensive nephropathy requiring renal biopsy and associated with increased proteinuria, not attributed to the COVID-19 lockdown period itself.
CONCLUSION
CONCLUSIONS
To our knowledge, this is the first report of identifying a subpopulation susceptible to closure of medical services during the COVID-19 pandemic and diagnostic delay of specific kidney diseases. Therefore, the COVID-19 pandemic should be regarded as a risk factor especially in patients with diseases other than COVID-19 primarily admitted to the normal medical ward.
Identifiants
pubmed: 34305628
doi: 10.3389/fphys.2021.649336
pmc: PMC8297651
doi:
Types de publication
Journal Article
Langues
eng
Pagination
649336Informations de copyright
Copyright © 2021 Hakroush, Tampe, Korsten and Tampe.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
EClinicalMedicine. 2020 Apr 23;22:100343
pubmed: 32328575
Lancet. 1992 Dec 12;340(8833):1435-6
pubmed: 1360561
Rheumatology (Oxford). 2021 Feb 1;60(2):617-628
pubmed: 32447389
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1551-1553
pubmed: 32846367
Nutrients. 2020 May 28;12(6):
pubmed: 32481594
J Hypertens. 2012 May;30(5):974-9
pubmed: 22495136
BMC Nephrol. 2017 Dec 29;18(1):378
pubmed: 29287588
Hypertens Res. 2007 Oct;30(10):937-43
pubmed: 18049025
Lancet Public Health. 2018 Jul;3(7):e323-e332
pubmed: 29908859
Exp Ther Med. 2013 Nov;6(5):1243-1246
pubmed: 24223652
Ann Rheum Dis. 2020 Dec 1;:
pubmed: 33262111
Kidney Int Suppl. 1994 Feb;45:S174-8
pubmed: 8158890
Rheumatology (Oxford). 2002 May;41(5):572-81
pubmed: 12011383
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1621-1623
pubmed: 32889403
Nat Med. 2020 May;26(5):647-648
pubmed: 32269357
Nutrients. 2020 May 26;12(6):
pubmed: 32466598
Kidney Int Rep. 2020 Sep;5(9):1545-1550
pubmed: 32838077
Ann Rheum Dis. 2021 Jan 6;:
pubmed: 33408078
BMJ. 2006 Jun 17;332(7555):1426
pubmed: 16714328
Kidney Int. 2004 Jun;65(6):2309-20
pubmed: 15149345
Front Public Health. 2021 Feb 01;8:584408
pubmed: 33598442
Am J Kidney Dis. 2000 Jun;35(6):1155-65
pubmed: 10845831
Intern Med. 2013;52(1):45-53
pubmed: 23291673
Ann Rheum Dis. 2020 Aug 11;:
pubmed: 32788397
Clin J Am Soc Nephrol. 2011 Oct;6(10):2364-73
pubmed: 21852664
BMC Nephrol. 2018 Jun 26;19(1):150
pubmed: 29940877
Nutrients. 2020 Aug 03;12(8):
pubmed: 32756458
Ann Rheum Dis. 2020 Aug 19;:
pubmed: 32816699
Lancet Glob Health. 2018 Oct;6(10):e1077-e1086
pubmed: 30193830